Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Protara Therapeutics, Inc. Director's Dealing 2015

Oct 19, 2015

34057_dirs_2015-10-19_ace2d6fa-677f-476f-9f4a-f22fbdb5282b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2015-10-16

Reporting Person: Kingsley Stuart A (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-10-16 Stock Option (Right to Buy) $15.21 A 13333 Acquired 2025-10-16 Common Stock, $0.001 par value (13333) Direct

Footnotes

F1: The options were granted on October 15, 2015 and will vest annually over a three-year period measured from the date of grant.